Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Vasopressin improves outcome in out-of-hospital cardiopulmonary resuscitation of ventricular fibrillation and pulseless ventricular tachycardia: a observational cohort study. | Available online http content 10 1 R13 Research Vasopressin improves outcome in out-of-hospital cardiopulmonary resuscitation of ventricular fibrillation and pulseless ventricular tachycardia a observational cohort study Stefek Grmec1 and Stefan Mally2 Assistant Professor Head of the Department Centre for Emergency Medicine Maribor University of Maribor Maribor Slovenia 2Medical Doctor Centre for Emergency Medicine Maribor Maribor Slovenia Corresponding author Stefan Mally Received 3 Aug 2005 Revisions received 24 Oct 2005 Accepted 1 2 Dec 2005 Published 6 Jan 2006 Critical Care 2006 10 R13 doi cc3967 This article is online at http content 10 1 R13 2006 Grmec and Mally licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Open Access Abstract Introduction An increasing body of evidence from laboratory and clinical studies suggests that vasopressin may represent a promising alternative vasopressor for use during cardiac arrest and resuscitation. Current guidelines for cardiopulmonary resuscitation recommend the use of adrenaline epinephrine with vasopressin considered only as a secondary option because of limited clinical data. Method The present study was conducted in a prehospital setting and included patients with ventricular fibrillation or pulseless ventricular tachycardia undergoing one of three treatments group I patients received only adrenaline 1 mg every 3 minutes group II patients received one intravenous dose of arginine vasopressine 40 IU after three doses of 1 mg epinephrine and patients in group III received vasopressin 40 IU as first-line therapy. The cause of cardiac arrest myocardial infarction or other cause was established for each patient in hospital. .
